miR-203 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting oncogene ADAM9 and oncogenic long non-coding RNA HULC

Anti-Cancer Agents in Medicinal Chemistry

Volumn 16, Issue 4, 2016, Pages 414-423

  Wan, Daiwei ^a,b   Shen, Shunli ^a   Fu, Shunjun ^a   Preston, Burnley ^b   Brandon, Coder ^b   He, Songbing ^c   Shen, Chenglong ^d   Wu, Jian ^a   Wang, Sutong ^a   Xie, Wenxuan ^a   Chen, Bin ^a   Liya, A ^a   Guo, Yixing ^e   Zheng, Dingcheng ^d   Zhi, Qiaoming ^d   Peng, Baogang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SOOCHOW UNIVERSITY   (China)

^e WANNAN MEDICAL COLLEGE   (China)

Author keywords

ADAM9; Hepatocellular carcinoma; HULC; Long non coding RNA; microRNA; miR 203

Indexed keywords

DISINTEGRIN; GELATINASE B; HEPATOCELLULAR CARCINOMA UP REGULATED LONG UNTRANSLATED RNA; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 203; UNCLASSIFIED DRUG; ADAM PROTEIN; ADAM9 PROTEIN, HUMAN; HULC LONG NON-CODING RNA, HUMAN; MEMBRANE PROTEIN; MIRN203 MICRORNA, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CELL INVASION ASSAY; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CLINICAL FEATURE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HULC GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; ONCOGENE; ONCOGENE ADAM9; OVERALL SURVIVAL; PROGNOSTIC ASSESSMENT; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; BIOSYNTHESIS; DEFICIENCY; GENETICS; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ADAM PROTEINS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; RNA, LONG NONCODING;

EID: 84961588799     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150716105955     Document Type: Article

References (34)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D., Global cancer statistics. CA Cancer J. Clin., 2011, 61, 69-90.
2. Bruix, J.; Gores, G.J.; Mazzaferro, V. Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut, 2014, 63, 844-855.
3. Pompili, M.; Francica, G.; Ponziani, F.R.; Iezzi, R.; Avolio, A.W. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J. Gastroenterol., 2013, 19, 7515-7530.
4. Kobayashi, T.; Ishiyama, K.; Ohdan, H. Prevention of recurrence after curative treatment for hepatocellular carcinoma. Surg. Today, 2013, 43, 1347-1354.
5. Miller, A.D., Delivering the promise of small ncRNA therapeutics. Ther. Deliv., 2014, 5, 569-589.
6. Ranganathan, K.; Sivasankar, V., MicroRNAs-Biology and clinical applications. J. Oral Maxillofac. Pathol., 2014, 18, 229-234.
7. Srinivasan, S.; Selvan, S.T.; Archunan, G.; Gulyas, B.; Padmanabhan, P. MicroRNAs -the next generation therapeutic targets in human diseases. Theranostics, 2013, 3, 930-942.
8. Sun, J.; Lu, H.; Wang, X.; Jin, H., MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications. Scient. World J., 2013, 924-206.
9. Li, C. H.; Chen, Y. Targeting long non-coding RNAs in cancers: Progress and prospects. Int. J. Biochem. Cell Biol., 2013, 45, 1895-1910.
10. Yang, G.; Lu, X.; Yuan, L. LncRNA: A link between RNA and cancer. Biochim. Biophys. Acta, 2014, 1839, 1097-1109.
11. Yang, L.; Froberg, J.E.; Lee, J.T. Long noncoding RNAs: Fresh perspectives into the RNA world. Trend. Biochem. Sci., 2014, 39, 35-43.
12. Cai, B.; Song, X.Q.; Cai, J.P.; Zhang, S., HOTAIR: A cancerrelated long non-coding RNA. Neoplasma, 2014, 61, 379-391.
13. Panzitt, K.; Tschernatsch, M.M.; Guelly, C.; Moustafa, T.; Stradner, M.; Strohmaier, H.M.; Buck, C.R.; Denk, H.; Schroeder, R.; Trauner, M.; Zatloukal, K. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology, 2007, 132, 330-342.
14. Chiyomaru, T.; Fukuhara, S.; Saini, S.; Majid, S.; Deng, G.; Shahryari, V.; Chang, I.; Tanaka, Y.; Enokida, H.; Nakagawa, M.; Dahiya, R.; Yamamura, S., Long non-coding RNA HOTAIR is targeted and regulated by miR-141 in human cancer cells. J. Biol. Chem., 2014, 289, 12550-12565.
15. Orom, U.A.; Lim, M.K.; Savage, J.E. Jin, L.; Saleh, A.D.; Lisanti, M.P.; Simone, N.L. MicroRNA-203 regulates caveolin-1 in breast tissue during caloric restriction. Cell Cycle, 2012, 11, 1291-1295.
16. Zhu, X.; Er, K.; Mao, C.; Yan, Q.; Xu, H.; Zhang, Y.; Zhu, J.; Cui, F.; Zhao, W.; Shi, H. miR-203 suppresses tumor growth and angiogenesis by targeting VEGFA in cervical cancer. Cellular Phys. Biochem., 2013, 32, 64-73.
17. Chiang, Y.; Song, Y.; Wang, Z.; Chen, Y.; Yue, Z.; Xu, H.; Xing, C.; Liu, Z. Aberrant expression of miR-203 and its clinical significance in gastric and colorectal cancers. J. Gastrointest. Surg., 2011, 15, 63-70.
18. Ikenaga, N.; Ohuchida, K.; Mizumoto, K.; Yu, J.; Kayashima, T.; Sakai, H.; Fujita, H.; Nakata, K.; Tanaka, M. MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann. Surg. Oncol., 2010, 17, 3120-3128.
19. Chen, H.Y.; Han, Z.B.; Fan, J.W.; Xia, J.; Wu, J.Y.; Qiu, G. Q.; Tang, H.M.; Peng, Z.H. miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. Med. Oncol., 2012, 29, 1859-1865.
20. Du, Y.; Kong, G.; You, X.; Zhang, S.; Zhang, T.; Gao, Y.; Ye, L.; Zhang, X. Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J. Biol. Chem., 2012, 287, 26302-26311.
21. VanGuilder, H.D.; Vrana, K.E.; Freeman, W.M. Twenty-five years of quantitative PCR for gene expression analysis. Biotechniques, 2008, 44, 619-626.
22. Zheng, K.; Chen, D.S.; Wu, Y.Q.; Xu, X.J.; Zhang, H.; Chen, C.F.; Chen, H.C.; Liu, Z.F. MicroRNA expression profile in RAW264.7 cells in response to Brucella melitensis infection. Int. J. Biol. Sci., 2012, 8, 1013-1022.
23. Lu, T.F.; Hua, X.W.; Cui, X. L.; Xia, Q. Liver transplantation for hepatocellular carcinoma: Recent advances in China. J. Dig. Dis., 2014, 15, 51-53.
24. Jang, W.I.; Kim, M.S.; Bae, S.H.; Cho, C.K.; Yoo, H.J.; Seo, Y.S.; Kang, J.K.; Kim, S.Y.; Lee, D. H.; Han, C.J.; Kim, J.; Park, S.C.; Kim, S.B.; Cho, E.H.; Kim, Y.H., High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat. Oncol., 2013, 8, 250.
25. Zhou, Y.; Wan, G.; Spizzo, R.; Ivan, C.; Mathur, R.; Hu, X.; Ye, X.; Lu, J.; Fan, F.; Xia, L.; Calin, G.A.; Ellis, L.M.; Lu, X. miR- 203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol. Oncol., 2014, 8, 83-92.
26. Wang, C.; Wang, X.; Liang, H.; Wang, T.; Yan, X.; Cao, M.; Wang, N.; Zhang, S.; Zen, K.; Zhang, C.; Chen, X. miR-203 inhibits cell proliferation and migration of lung cancer cells by targeting PKCalpha. PLoS One, 2013, 8, e73985.
27. Takeshita, N.; Mori, M.; Kano, M.; Hoshino, I.; Akutsu, Y.; Hanari, N.; Yoneyama, Y.; Ikeda, N.; Isozaki, Y.; Maruyama, T.; Akanuma, N.; Miyazawa, Y.; Matsubara, H. miR-203 inhibits the migration and invasion of esophageal squamous cell carcinoma by regulating LASP1. Int. J. Oncol., 2012, 41, 1653-1661.
28. Klein, T.; Bischoff, R. Active metalloproteases of the A disintegrin and metalloprotease (ADAM) family: biological function and structure. J. Proteome. Res., 2011, 10, 17-33.
29. Van der Vorst, E.P.; Keijbeck, A.A.; De Winther, M.P.; Donners, M.M., A disintegrin and metalloproteases: Molecular scissors in angiogenesis, inflammation and atherosclerosis. Atherosclerosis, 2012, 224, 302-308.
30. Sher, Y.P.; Wang, L.J.; Chuang, L.L.; Tsai, M.H.; Kuo, T.T.; Huang, C.C.; Chuang, E.Y.; Lai, L.C. ADAM9 up-regulates Ncadherin via miR-218 suppression in lung adenocarcinoma cells. PLoSOne, 2014, 9, e94065.
31. Zigrino, P.; Nischt, R.; Mauch, C., The disintegrin-like and cysteine-rich domains of ADAM-9 mediate interactions between melanoma cells and fibroblasts. J. Biol. Chem., 2011, 286, 6801-6807.
32. Carl-McGrath, S.; Lendeckel, U.; Ebert, M.; Roessner, A.; Rocken, C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int. J. Oncol., 2005, 26, 17-24.
33. Tao, K.; Qian, N.; Tang, Y.; Ti, Z.; Song, W.; Cao, D.; Dou, K., Increased expression of a disintegrin and metalloprotease-9 in hepatocellular carcinoma: Implications for tumor progression and prognosis. JPN. J. Clin. Oncol., 2010, 40, 645-651.
34. Zhao, Y.; Guo, Q.; Chen, J.; Hu, J.; Wang, S.; Sun, Y., Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: A clinical and in vitro investigation. Oncol. Rep., 2014, 31, 358-364.